Initial focus for CLAR-121 is the treatment of periductal mastitis (PDM) in women
Clarus is seeking Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in the second quarter of 2022
Initiation of Phase 2 clinical trial for CLAR-121 for the treatment of PDM anticipated in the second half of 2022
NORTHBROOK, Ill., May 10, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for claims that cover certain methods for the treatment of autoimmune inflammatory mastitis that can be achieved by its product candidate, CLAR-121, a proprietary combination of testosterone (T) and anastrozole delivered by a subcutaneous implant.
Patent application No. 17/437,525 is entitled “Pharmaceutical Formulations and Systems for Delivery of an Androgenic Agent and an Aromatase Inhibitor with Sustained Multi-Phasic Release Profiles and Methods of Use.” The U.S. patent scheduled to issue from this application will expire in June 2040.
“We are thrilled to further establish intellectual property protection for our pipeline,” said Dr. Robert Dudley, President and Chief Executive Officer of Clarus. “We believe this notice of allowance validates the innovation behind CLAR-121 and supports this novel approach for treating androgen-mediated inflammatory breast diseases. Our initial focus for CLAR-121 will be for the treatment of PDM, a painful condition of inflamed breast tissue that predominantly affects women and for which there is currently no available drug interventions. We are currently seeking Orphan Drug Designation from the FDA for CLAR-121 for the treatment of PDM in the second quarter of 2022 and anticipate initiating a Phase 2 clinical trial in the second half of 2022.”
About CLAR-121 (Testosterone + Anastrozole) for Inflammatory Periductal Mastitis (PDM) CLAR-121 is a proprietary combination of T (natural ligand for the androgen receptor (AR)) and anastrozole (an aromatase inhibitor that blocks T conversion to estradiol) delivered by a subcutaneous implant for the treatment of AR-mediated inflammatory breast disease that predominantly affects women. Clarus acquired development and commercialization rights from Australia-based HavaH Therapeutics in May 2021. Clarus initially plans to target inflammatory PDM, also known as Zuska’s Disease. PDM is a painful, often debilitating inflammation of breast tissue that affects approximately 150,000 women in the United States each year. There is no known effective drug treatment for PDM, and often the only medical intervention is disfiguring surgery. Clarus currently is seeking Orphan Drug Designation from the FDA for CLAR-121 for the treatment of PDM in the second quarter of 2022. Clarus also plans to initiate a Phase 2 clinical trial for CLAR-121 for the treatment of PDM in the second half of 2022, subject to the availability of funding.
About Clarus Therapeutics Holdings, Inc. Clarus Therapeutics Holdings, Inc. is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women – including potential therapies for orphan indications. Clarus’ first commercial product is JATENZO® (testosterone undecanoate). For more information, visit www.clarustherapeutics.com and www.jatenzo.com. Follow us on Twitter (@Clarus_Thera) and LinkedIn (Clarus Therapeutics).
Clarus Forward-Looking Statements Certain statements in this press release constitute “forward-looking statements” for purposes of the federal securities laws. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Clarus’ forward-looking statements in this press release include, but are not limited to, statements regarding the issuance and timing of expiration of a new patent covering CLAR-121, seeking orphan drug status for CLAR-121, and initiation of a Phase 2 clinical trial for CLAR-121 for the treatment of PDM. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting us will be those that Clarus has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Clarus’ control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks associated with pharmaceutical development, risks associated with Clarus’ financial position, and those factors described under the heading “Risk Factors” in Clarus’ annual report on 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission (the SEC) on March 31, 2022, and those that are included in any of Clarus’ future filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of Clarus’ assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Some of these risks and uncertainties may in the future be amplified by the ongoing COVID-19 pandemic and there may be additional risks that Clarus considers immaterial, or which are unknown. It is not possible to predict or identify all such risks. Clarus’ forward-looking statements only speak as of the date they are made, and Clarus does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
JATENZO® is a registered trademark of Clarus Therapeutics Holdings, Inc.
Clarus Contact: Kara Stancell Vice President, Investor Relations & Corporate Communications kstancell@clarustherapeutics.com (847) 562-4300 x 206
U.S. Food and Drug Administration staff said on Friday Novavax Inc's vaccine reduces the risk of mild-to-severe COVID-19 and that it was likely the shot could provide some level of protection against the Omicron variant. The FDA analyzed data from Novavax's trial before the Omicron and Delta variant became the dominant strains. "Based on the efficacy estimate in the clinical trial of this vaccine, it is more likely than not that the vaccine will provide some meaningful level of protection against COVID-19 due to Omicron, in particular against more severe disease," FDA staff said.
The FDA suggested Friday there could be a link between Novavax's Covid vaccine and heart inflammation, and NVAX stock plummeted.
(Bloomberg) -- Novavax Inc. slumped 20% on Friday after US regulators raised concerns over the biotech’s much-anticipated Covid-19 vaccine. Most Read from BloombergOne-Third of Americans Making $250,000 Live Paycheck-to-Paycheck, Survey FindsTesla Pauses Hiring as Musk Aims for 10% Staff Cut, Reuters Says‘Most Clever Oligarch’ Severed His $37 Billion Fortune From Russian RootsElon Musk’s Ultimatum to Tesla Execs: Return to the Office or Get OutStocks Resume Weekly Losses as Jobs Fuel Rate Bets:
'Multiple events' of heart inflammation were reported after administering the Covid-19 vaccine, especially among younger men, according to the FDA.
Novavax Inc.’s (NASDAQ: NVAX) stock tanked more than 20% Friday afternoon after the Food and Drug Administration shared concerns about a potential connection between heart inflammation and the company’s experimental Covid-19 vaccine, which the agency expects to take into consideration next week for potential emergency use authorization. As part of a briefing released Friday, the FDA said its vaccines advisory committee will meet Tuesday to discuss the Gaithersburg company's submission and “provide recommendations on whether, based on the totality of scientific evidence available, the benefits of the Novavax Covid-19 Vaccine 2-dose primary series outweigh its risks for use in individuals 18 years of age and older.” The risks, according to the documents, namely include the potential for inflammation in and around the heart, known as myocarditis and pericarditis.
There are two sides to every coin. For penny stocks, or tickers that trade for less than $5 per share, this rings especially true. As some of the most divisive names on the Street, they are either met with resounding praise or forceful discontent. Going beyond the argument that you get more for your money, even minor price appreciation can result in massive percentage gains. However, some investors prefer to avoid these stocks entirely, as the fact that shares are trading at such depressed level
Pharmaceutical behemoth Pfizer (NYSE: PFE) has racked up successes during the COVID-19 outbreak, as the first to enter the market with a vaccine in December 2020 and a pill treatment in December 2021. Outside of the Covid space, Pfizer sells a number of megablockbusters such as blood-thinner Eliquis, breast-cancer drug Ibrance, pneumonia vaccine Prevnar, and arthritis treatment Xeljanz. The company also sees higher growth coming from blockbuster drugs Vyndaqel for cardiovascular disease and Inlyta and Xtandi for cancer treatments.
Regeneron Pharmaceuticals (NASDAQ: REGN) had a day to forget, at least as far as its stock was concerned. Regeneron announced that it's buying out its partner Sanofi's (NASDAQ: SNY) stake in Libtayo, the cancer drug on which they've collaborated. Under the terms of the arrangement, Regeneron would hold the exclusive development, commercialization, and manufacturing rights to the medication worldwide.
Drug development is time-consuming, expensive, and full of failure. From 2011 to 2020, only 7.9% of drug candidates that began a phase 1 clinical trial earned approval from the U.S. Food and Drug Administration (FDA). Centessa Pharmaceuticals was founded to attack the inefficiency of drug development head on.
Even if you're keeping up with the latest official recommendations about COVID- prevention, this may be an uncertain and frustrating time. As summer approaches, what is safe to do? How should we approach social activities now that it's clear COVID is a chronic part of our lives? Here's an important overlooked factor one doctor wishes we knew about COVID now. Her point: We need to consider what's safe, but also what's healthy. Read on to find out more—and to ensure your health and the health of o
Americans may soon get a new COVID-19 vaccine option — a more traditional kind of shot known as a protein vaccine.
Shares of Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company that specializes in brain disorder therapies, saw its shares rise 15.6% this week, according to data from S&P Global Market Intelligence. The company announced on Wednesday that zuranolone, a drug it is developing with Biogen, had met its primary endpoints in a phase 3 study to treat women with postpartum depression. According to the release, the women who were treated with 50 milligrams of the therapy showed significant and meaningful improvement in depression symptoms.
(Reuters) -The U.S. Food and Drug Administration has raised concerns about a possible risk of heart inflammation from Novavax Inc's COVID-19 vaccine, even as the company's data showed it could reduce the chances of mild-to-severe disease. In Novavax's nearly 30,000 patient trial, conducted between December 2020 and September 2021, there were four cases of a type of heart inflammation called myocarditis detected within 20 days of taking the protein-based shot.
The bathroom means different things to different people. For some, it's simply where they use the toilet, grab a quick shower, and tend to various hygiene habits. For others, it's a quiet space where they can have a little time to themselves—or a lot of time. A 2019 survey out of the UK revealed that the average person spends more than 400 days of their life in the bathroom, with one in six adults saying they hang out in the bathroom for peace and quiet.While various activities can take place in
(Reuters) -Bristol Myers Squibb Co said on Friday it will acquire drug developer Turning Point Therapeutics Inc for $4.1 billion in cash to help bolster its arsenal of cancer drugs. Bristol Myers will pay $76 per Turning Point share, a 122.5% premium to its last closing price. The deal "will surprise many investors who over the past year have begun to believe late-to-market targeted oncology drugs are likely to be commercial failures," Stifel analyst Bradley Canino said.
Out of all tick diseases, Illinois residents should worry most about Lyme disease. There were 539 cases in Illinois in 2021, according to the IDPH.
Over the last two years, the coronavirus has made one million Americans so severely ill that they have died as a result. While that tragic outcome is a worst case scenario, there are a wide variety of ways a COVID case can pan out. Many people don't even know they're infected until they test positive because they never develop symptoms, while others get sick enough to need hospitalization. The Centers for Disease Control and Prevention (CDC) has pinpointed a number of factors that could make you
Vaginismus is an involuntary tightening of the vaginal muscles, which can make everything from sex to inserting tampons painful.
Scientists in China may have found a way to potentially reverse the aging process via a technique that can be described as “vampiric.” Published last month in the peer-reviewed journal Cell Stem Cell, the study led by the Chinese Academy of Sciences involved surgically connecting the circulatory systems of old mice to those of younger specimens. Up until recently, the actual impact that young blood has on older circulatory systems remained a mystery.
Many people who have taken Paxlovid are reporting a return of symptoms. Here's why it may be happening, and why doctors still recommend using the medication.